

| OMB APPROVAL                                 |           |
|--|-----------|
| OMB Number:                                  | 3235-0287 |
| Estimated average burden hours per response: | 0.5       |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

|  |   |   |
|--|---|---|
| 1. Name and Address of Reporting Person*<br><u>Versant Venture Capital VI, L.P.</u><br><br>(Last) (First) (Middle)<br>ONE SANSOME STREET, SUITE 3630<br><br>(Street)<br>SAN FRANCISCO CA 94104<br><br>(City) (State) (Zip) | 2. Issuer Name and Ticker or Trading Symbol<br><u>Century Therapeutics, Inc. [ IPSC ]</u> | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)<br><br>Director <input checked="" type="checkbox"/> 10% Owner<br><br>Officer (give title below) Other (specify below) |
|  | 3. Date of Earliest Transaction (Month/Day/Year)<br>06/22/2021                            |   |
|  | 4. If Amendment, Date of Original Filed (Month/Day/Year)                                  |   |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) |   | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) |            |       | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|-------|---|--|---|
|                                 |                                      |  | Code                           | V | Amount  | (A) or (D) | Price |   |  |   |
| Common Stock                    | 06/22/2021                           |  | C                              |   | 9,936,011   | A          | (1)   | 12,916,814  | D <sup>(2)</sup>   |   |
| Common Stock                    | 06/22/2021                           |  | C                              |   | 614,095   | A          | (3)   | 614,095   | I  | See footnote <sup>(4)</sup>                           |
| Common Stock                    | 06/22/2021                           |  | P                              |   | 100,000   | A          | \$20  | 714,095   | I  | See footnote <sup>(4)</sup>                           |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |   | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |     | 6. Date Exercisable and Expiration Date (Month/Day/Year) |                 | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|-----|--|-----------------|---|--|--|---|--|
|  |  |                                      |  | Code                           | V | (A)  | (D) | Date Exercisable   | Expiration Date |   |  |  |   |  |
| Series A Preferred Stock                   | (1)  | 06/22/2021                           |  | C                              |   | 25,000,000   | (1) | (1)  | Common Stock    | 9,936,011 <sup>(1)</sup>  | \$0  | 0  | D <sup>(2)</sup>  |  |
| Series C Preferred Stock                   | (3)  | 06/22/2021                           |  | C                              |   | 1,545,125  | (3) | (3)  | Common Stock    | 614,095 <sup>(3)</sup>  | \$0  | 0  | I   | See footnote <sup>(4)</sup>                            |

1. Name and Address of Reporting Person\*  
Versant Venture Capital VI, L.P.  
 (Last) (First) (Middle)  
 ONE SANSOME STREET, SUITE 3630  
 (Street)  
 SAN FRANCISCO CA 94104  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Versant Ventures VI GP, L.P.  
 (Last) (First) (Middle)  
 ONE SANSOME STREET, SUITE 3630  
 (Street)  
 SAN FRANCISCO CA 94104  
 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Versant Ventures VI GP-GP, LLC  
 (Last) (First) (Middle)  
 ONE SANSOME STREET, SUITE 3630  
 (Street)

|   |         |          |
|---|---------|----------|
| SAN FRANCISCO                                 | CA      | 94104    |
| (City)  | (State) | (Zip)    |
| 1. Name and Address of Reporting Person*      |         |          |
| <a href="#">Versant Vantage II, L.P.</a>      |         |          |
| (Last)  | (First) | (Middle) |
| ONE SANSOME STREET, SUITE 3630                |         |          |
| (Street)                                      |         |          |
| SAN FRANCISCO                                 | CA      | 94104    |
| (City)  | (State) | (Zip)    |
| 1. Name and Address of Reporting Person*      |         |          |
| <a href="#">Versant Vantage II GP, L.P.</a>   |         |          |
| (Last)  | (First) | (Middle) |
| ONE SANSOME STREET, SUITE 3630                |         |          |
| (Street)                                      |         |          |
| SAN FRANCISCO                                 | CA      | 94104    |
| (City)  | (State) | (Zip)    |
| 1. Name and Address of Reporting Person*      |         |          |
| <a href="#">Versant Vantage II GP-GP, LLC</a> |         |          |
| (Last)  | (First) | (Middle) |
| ONE SANSOME STREET, SUITE 3630                |         |          |
| (Street)                                      |         |          |
| SAN FRANCISCO                                 | CA      | 94104    |
| (City)  | (State) | (Zip)    |

**Explanation of Responses:**

- Shares of Series A Preferred Stock automatically converted into shares of Common Stock at a 2.5161-for-1 conversion rate immediately prior to the closing of the Issuer's initial public offering and have no expiration date.
- The reportable securities are owned directly by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Versant Ventures VI GP and Versant Ventures VI GP-GP may be deemed to indirectly beneficially own the shares beneficially owned by Versant VI, but disclaim beneficial ownership except to the extent of their pecuniary interest therein.
- Shares of Series C Preferred Stock automatically converted into shares of Common Stock at a 2.5161-for-1 conversion rate immediately prior to the closing of the Issuer's initial public offering and have no expiration date.
- The reportable securities are owned by Versant Vantage II, L.P. ("Versant Vantage II"). Versant Vantage II GP, L.P. ("Versant Vantage II GP") is the general partner of Versant Vantage II, and Versant Vantage II GP-GP, LLC ("Versant Vantage II GP-GP") is the general partner of Versant Vantage II GP. Versant Vantage II GP and Versant Vantage II GP-GP may be deemed to indirectly beneficially own the shares beneficially owned by Versant Vantage II, but disclaim beneficial ownership except to the extent of their pecuniary interest therein.

[By: /s/ Versant Venture Capital VI, L.P. By: Versant Ventures VI GP, L.P. Its: General Partner By: Versant Ventures VI GP-GP, LLC Its: General Partner By: Robin L. Praeger Its: Managing Director](#) 06/23/2021  
[By: /s/ Versant Ventures VI GP, L.P. By: Versant Ventures VI GP-GP, LLC Its: General Partner By: Robin L. Praeger Its: Managing Director](#) 06/23/2021  
[By: /s/ Versant Ventures VI GP-GP, LLC By: Robin L. Praeger Its: Managing Director](#) 06/23/2021  
[By: /s/ Versant Vantage II, L.P. By: Versant Vantage II GP, L.P. Its: General Partner By: Versant Vantage II GP-GP, LLC Its: General Partner By: Robin L. Praeger Its: Managing Director](#) 06/23/2021  
[By: /s/ Versant Vantage II GP, L.P. By: Versant Vantage II GP-GP, LLC Its: General Partner By: Robin L. Praeger Its: Managing Director](#) 06/23/2021  
[By: /s/ Versant Vantage II GP-GP, LLC By: Robin L. Praeger Its: Managing Director](#) 06/23/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**